---
title: Knowledge Base Retrieval and Recall for Biologics Investment Research Knowledge Base Construction
slug: /en/industry/finance-d006-c105-f013
page_type: Industry scenario page
article_section: Research Knowledge Base Governance
is_part_of: FastGPT Tech Center
meta_title: Knowledge Base Retrieval and Recall for Biologics Investment
meta_description: Biologics investment research data primarily comes from clinical trial registration platforms, pharmaceutical company R&D pipeline announcements
source_type: Industry topic matrix (industry x direction x capability x real community questions)
date_published: 2026-09-15
date_modified: 2026-09-15
---

# Knowledge Base Retrieval and Recall for Biologics Investment Research Knowledge Base Construction

## What Data for This Category Looks Like
Biologics investment research data primarily comes from clinical trial registration platforms, pharmaceutical company R&D pipeline announcements, patent databases, industry regulatory agency public documents, and professional research reports.
Data update cycles vary significantly by source. Clinical trial data updates in real time alongside trial enrollment, unblinding, and other milestones. Corporate pipeline information updates with quarterly announcements. Patent data syncs in real time as patents are authorized and published.
Documents include structured fields and unstructured content. Structured fields include drug generic names, targets, clinical trial phases, number of enrolled subjects (unit: cases), administration dose (unit: mg/kg), and more. Unstructured content includes trial protocols, safety evaluation reports, and R&D progress descriptions.

## Constraints Imposed on Retrieval and Recall
The multi-source, multi-structure nature of biologics investment research data creates multiple constraints for the retrieval and recall process.
Structured fields are numerous and have dedicated units. Retrieval must support field-level precise matching and unit recognition. This prevents recall result deviations caused by unit confusion.
Unstructured documents have long lengths, and format differences across sources are significant. The parsing process must adapt to multi-format files and support long text segmentation.
Data update cycles vary widely. The system must support incremental update mechanisms. This ensures recall results include the latest clinical trial unblinding information and pipeline changes.
Investment research scenarios have high timeliness requirements. Recall ranking rules that prioritize timeliness weights must be configured.

## Configuration Settings
| Configuration Item | Recommended Value | Rationale |
| --- | --- | --- |
| `Recall Count` | `Top 8–12 results` | Biologics investment research documents contain extensive professional details. This range covers key R&D pipeline, clinical trial, and regulatory public information, while avoiding content truncation caused by exceeding the context window |
| `Similarity Threshold` | `0.70–0.82` | Biologics professional terminology has high recognition accuracy. A threshold that is too low introduces irrelevant documents. A threshold that is too high may miss pipeline information for similar targets. This range balances precision and recall coverage |
| `Segment Length` | `900–1100 characters` | Documents such as biologics trial reports and research reports have long lengths. This segment length preserves complete trial phase, administration dose, and safety data, while avoiding excessively long single segments that reduce retrieval accuracy |
| `PARSE_FILE_TIMEOUT_SECONDS` | `240–360 seconds` | Parsing large documents such as patent files and long research reports takes significant time. This range covers the parsing process for most unstructured documents, avoiding parsing timeout failures |
| `Enable Field-Level Retrieval` | `Enabled` | Biologics data includes structured fields such as targets, clinical trial phases, and administration doses. Enabling field-level retrieval enables precise matching, avoiding recall deviations caused by vague keyword matching |

> The parameter values provided on this page are common recommended starting points for configuration. Actual values are affected by material format, data volume, and business rules. Specific issues require individual analysis. It is recommended to test on your own samples before finalizing settings.

## Three Common Mistakes
- A "Request failed with status code 400" error occurs when uploading biologics clinical trial documents. Cause: The administration dose units (such as mg/kg) contained in the document are not correctly recognized as structured fields. This causes parameter format verification to fail for the upload interface.
- Response lag occurs when retrieving biologics investment research content. Cause: The `Segment Length` and `Recall Count` parameters are not adjusted. Excessively long segments and too many recall results exceed the context window. This increases model inference time.
- Precise recall of corresponding documents by drug generic name fails. Cause: Field-level retrieval configuration is not enabled. Only the main body content is vectorized. This prevents title fields such as drug generic names from being effectively matched.

## How to Verify Proper Configuration
- A biologics document containing structured fields is uploaded. Successful parsing of target, administration dose, and other fields is verified in the upload log.
- A retrieval targeting a drug target is initiated. Recall results are checked to confirm they include documents matching the target, and the number of results falls within the configured recall count range.
- A recently updated R&D announcement document is uploaded. The incremental update process is allowed to complete, then a retrieval is initiated to confirm the latest document is included in recall results.
- Retrieval tests using administration dose keywords with different units are conducted. Results for the same dose with different units are verified to not be incorrectly mixed.

> Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-14.
